Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Vivani Medical, Inc. filings on SEC EDGAR ↗
Vivani Medical entered into a share purchase agreement for a $5.1 million private placement of common stock with board members Gregg Williams and Aaron Mendelsohn. The shares were priced at $1.01 per share, representing an at-the-market transaction based on the prior trading day's close. Proceeds will be used to fund the clinical development of NPM-139, the company's semaglutide implant for weight maintenance.
Vivani Medical Insider Gregg Williams Buys $47.8K of Stock
Gregg Williams bought 48,100 shares of Vivani Medical, Inc. at $0.993 a share, worth $47.8K in total on Nov 13, 2026. Shares held after the trade: 36,960,836 (+0.1%).
Vivani Medical Chief Business Officer Donald Dwyer Buys $15.5K of Stock
Donald Dwyer, Chief Business Officer, bought 15,000 shares of Vivani Medical, Inc. at $1.03 a share, worth $15.5K in total on Nov 12, 2026. Shares held after the trade: 75,000 (+25.0%).
Vivani Medical announced positive top-line results from its SLIM-1 Phase 1 trial evaluating NPM-139, a miniature semaglutide implant for chronic weight management. The trial demonstrated that NPM-139 was well-tolerated with no treatment-related adverse events and achieved weight loss of 0.79% over four weeks, comparable to the 0.82% observed in the Wegovy control group.
Term
4 weeks
“The third quarter and recent weeks mark a period of strong progress and forward momentum for Vivani. The top-line SLIM-1 results will be announced this week. We look forward to sharing those results with shareholders, industry peers, and the broader community of physicians and patients seeking less frequent dosing and the promise of potential improvements in convenience, medication adherence, and tolerability associated with GLP-1 therapies on the market and in clinical-stage development.”
Adam Mendelsohn, PhD, CEO
“Roughly half of patients don’t take their medications for chronic diseases as prescribed, and GLP-1 therapies are no exception. With NPM-139, we are designing a novel GLP-1 therapy that a patient could receive once or twice a year during a routine primary care visit.”
Vivani Medical, Inc. is a clinical-stage company with a cash balance of $14.6 million as of September 30, 2026, down from $16.2 million at year-end 2025. The company remains pre-revenue, focusing on the development of product candidates like NPM-139 and NPM-133, and reported a total liability of $22.1 million primarily driven by lease obligations.
Vivani Medical provided a status update on the pending merger of its subsidiary Cortigent, Inc. with ClearOne, Inc. The company noted that while the deal was expected to close in October 2026, it remains subject to final regulatory approval and is now expected to close shortly after such approval is received.
Vivani Medical, Inc. filed an updated corporate slide presentation to provide business updates and summaries to the investment community. The presentation, dated October 29, 2026, is intended for use at various industry and investor conferences.